Gt Biopharma Inc Stock Price, News & Analysis

GT Biopharma, Inc. (NASDAQ: GTBP) announced it has raised over $16 million from the exercise of warrants, part of a $27 million financing completed in February 2021. This funding strengthens the company's financial position, enabling further development of its drug candidates, including GTB-4550, GTB-5550, and GTB-6550. GTB-3550 is currently in FDA Phase 1 Clinical Trial with 12 patients treated, and results are expected to be published in September 2021. The company has approximately $40 million in its treasury for ongoing drug development.

GT Biopharma announces a sponsored research agreement with Dr. Jeffrey Miller from the University of Minnesota to enhance the clinical development of its TriKE™ therapeutics for cancer treatment. The contract, valued at $2,074,686, spans two years with quarterly payments and allows GT Biopharma exclusive rights to patentable inventions. TriKE™ has shown effectiveness in reviving NK cells and reducing cancer cell burdens without significant toxicities in clinical trials. Positive results were reported in the GTB-3550 TriKE™ trial, including a 57% reduction in cancer cell burden in some patients.

GT Biopharma, Inc. (NASDAQ: GTBP) announced that CEO Tony Cataldo will present at Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. The summit is known for bringing together prestigious family offices and investors from over 30 countries, representing more than $4.5 trillion in wealth. GT Biopharma specializes in immuno-oncology therapeutics, utilizing its proprietary TriKE™ NK cell engager technology platform to enhance patients' natural killer cells for cancer treatment. For more information, visit gtbiopharma.com.

GT Biopharma announced interim clinical trial results of GTB-3550 TriKE™ at the Raymond James Health Innovation Conference. The Phase 1 trial targets high-risk MDS and refractory AML, with 57% of patients showing a notable reduction in cancer cell burden. Bone marrow blast levels decreased by up to 63.7%, and the treatment was well tolerated without significant side effects. Eleven patients completed treatment, and the trial will assess safety and recommend a Phase 2 dose, with results expected by September 2021.

GT Biopharma announced that Dr. Jeffrey S. Miller will update on the GTB-3550 TriKE™ Phase I trial at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. This session will accompany the Company's corporate update presentation. A live webcast will be available on GT Biopharma's website, with a replay archived for 30 days post-event. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE™ NK cell engager technology, developed in partnership with the University of Minnesota.

GT Biopharma, a clinical stage immuno-oncology company, will provide a corporate update at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. The presentation will showcase developments from their proprietary TriKE™ NK cell engager platform. A live webcast can be accessed via the company's website, with an archive available for 30 days post-event. GT Biopharma holds an exclusive agreement with the University of Minnesota for further therapy development.

GT Biopharma, Inc. (NASDAQ: GTBP) announced its inclusion in the Russell 2000 Index, effective June 28, 2021. This milestone reflects the company's progress in developing its TriKE™ NK cell engager technology. CEO Anthony J. Cataldo emphasized the importance of this recognition for enhancing visibility and growth potential. The Russell 2000 Index is significant for institutional investors, with approximately $9 trillion in assets benchmarked against Russell's U.S. indexes. The inclusion is expected to attract broader investment interest and support GT Biopharma's long-term objectives.

GT Biopharma, Inc. (NASDAQ: GTBP) announced a call with Dr. Jeffrey S. Miller on May 19, 2021, at 4:00 PM ET, to discuss interim results from its Phase I/II clinical trial of GTB-3550 TriKE™. Key highlights include a 63.7% reduction in bone marrow blast levels in patients with high-risk MDS and AML and a successful restoration of NK cell functions. Enrollment for the trial is ongoing, with the potential for accelerated approval based on new endpoints. A live webcast will be available for those interested.

GT Biopharma, Inc. (NASDAQ: GTBP) reported its Q1 2021 results on May 17, highlighting encouraging data from the Phase I/II trial of GTB-3550 TriKE™ for MDS and AML. The trial showed up to a 63.7% reduction in bone marrow blast levels with no cytokine release syndrome observed. The company completed a $28.7M financing boosting its cash position to $35M. R&D expenses rose to $1.6M, and general administrative expenses increased significantly to $27.3M due to stock-based compensation, resulting in a net loss of $29.7M.